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Abstract 
Background: The blood–brain barrier (BBB) is a complex physical and functional barrier protecting the central 
nervous system from physical and chemical insults. Nevertheless, it also constitutes a barrier against therapeutics 
for treating neurological disorders. In this context, nanomaterial‑based therapy provides a potential alternative for 
overcoming this problem. Graphene family has attracted significant interest in nanomedicine because their unique 
physicochemical properties make them amenable to applications in drug/gene delivery and neural interface.
Results: In this study, reduced graphene oxide (rGO) systemically‑injected was found mainly located in the thalamus 
and hippocampus of rats. The entry of rGO involved a transitory decrease in the BBB paracellular tightness, as demon‑
strated at anatomical (Evans blue dye infusion), subcellular (transmission electron microscopy) and molecular (junc‑
tional protein expression) levels. Additionally, we examined the usefulness of matrix‑assisted laser desorption/ioniza‑
tion (MALDI) mass spectrometry imaging (MSI) as a new imaging method for detecting the temporal distribution of 
nanomaterials throughout the brain.
Conclusions: rGO was able to be detected and monitored in the brain over time provided by a novel application 
for MALDI‑MSI and could be a useful tool for treating a variety of brain disorders that are normally unresponsive to 
conventional treatment because of BBB impermeability.
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Background
The blood–brain barrier (BBB) has an intricate physi-
cal and molecular structure that provides a proper 
microenvironment for neuronal cell activity. The physi-
cal structure consists of a fenestration-free continuous 
endothelium and a surrounding basement membrane 
covered by a sheath of distal end-feet of astrocytes pro-
cesses and pericytes. The molecular structure consists of 
a collection of membrane receptors and highly selective 
carriers that regulate the bi-directional trans-endothelial 
movement of molecules across the blood–brain inter-
face. The inter-endothelial trafficking of molecules is 
prevented by an elaborate, closely applied junctional 
contact that is provided by tight junctional and adhesion 
transmembrane proteins, some of which are anchored 
to the cell cytoskeleton. Such an intricate arrangement 
results in brain endothelial lining that has a very high 
electrical resistance compared to peripheral vascular 
endothelium [1]. The BBB is a highly dynamic struc-
ture that responds to minimal changes in the circulating 
blood and brain microenvironment through self-adjust-
ing mechanisms that serve to protect neuronal activity. 
However, the complexity of the physical and molecular 
arrangement of the BBB precludes the accessibility of 
many drugs to the central nervous system. As a conse-
quence, various neurological disorders remain untreat-
able and this can be an important cause of precocious 
death.
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The emerging interdisciplinary field of nanotechnol-
ogy could provide a means of overcoming the restric-
tive nature of the BBB with regard to drug entry into 
the brain. There has been considerable effort in search-
ing for nanoscale-dimensioned materials amenable to 
crossing the BBB and delivering drugs to specific sites 
of injury [2]. Among these nanomaterials, graphene 
and derivatives, such as reduced graphene oxide (rGO), 
have attracted significant interest; their free π electrons 
and extremely high surface area allow interaction with 
a variety of biomolecules, making them particularly 
amenable to applications in tissue engineering, molec-
ular imaging, drug/gene delivery [3] and neural inter-
faces [4, 5].
An important aspect in the development of drug 
nanocarriers is that of ascertaining their fate in the 
brain and determining the amount and the way they 
reached the target. A number of in vivo techniques have 
been developed to detect and measure the uptake of 
drug nanocarriers in the brain. Usually, scanning and 
transmission electron microscopy (TEM), fluorescence 
microscopy, confocal laser microscopy and pharma-
cokinetic and biodistribution studies have been used 
for this purpose [6]. However, these techniques present 
substantial technical challenges and monitoring the 
spatial distribution of nanomaterials over time is not 
always easy or fast.
In recent years, matrix-assisted laser desorption/ioni-
zation (MALDI) mass spectrometry imaging (MSI) has 
emerged as a powerful methodology to investigate the 
spatial distribution of specific biomolecules in tissue sec-
tions [7]. MALDI-MSI has been used to visualize atoms 
and small molecules at spatial resolutions below one 
micron [8, 9], which is close to that of nanoparticles with 
at least one dimension ≤100 nm [10]. The present study 
was undertaken to test the hypothesis that MALDI-
MSI could be used to detect and follow the spatial den-
sity of rGO in the brain. For comparative purposes, we 
also assessed the detection of rGO by confocal laser 
microcopy.
Another highly significant aspect to consider when 
studying drug transport and delivery to the brain via 
nanomaterials relates to the integrity of the BBB through-
out treatment. To address this matter, we used three 
approaches to examine BBB integrity, namely: (a) gross 
anatomical observation based on the peripheral infusion 
of Evans blue dye, (b) sub-cellular evaluation by TEM 
in conjunction with the extracellular tracer lanthanum 
nitrate to determine whether the tracer escaped into 
the brain parenchyma, and (c) western blotting (WB) 
to assess possible cell–cell or cell–matrix disarray in 
endothelial tight and adhesion junctional proteins and 
laminin in brain tissue homogenates.
Results and discussion
Physicochemical characterization of rGO
The uptake of nanoscale materials from the circulation 
and their internalization by the brain depends on their 
physicochemical characteristics, such as morphology, 
composition, uniformity, size and surface charge [11]. 
Graphene is composed of a single-atom-thick sheet of 
sp2-bonded carbon atoms hexagonally arranged in a two-
dimensional structure that creates a large surface area 
on both sides of the planar axis. Graphene family-based 
nanomaterials include single- or few-layer-graphene, 
ultrathin graphite, graphene oxide, and rGO [12].
rGO was the product of treating graphene oxide under 
reducing conditions (chemical, thermal, microwave, 
photo-chemical, photo-thermal or microbial/bacterial) 
in order to reduce its oxygen content [13]. The reduc-
tion degree of the rGO engineered in our laboratory 
was investigated using UV–Visible spectroscopy. rGO in 
water results in a black suspension (inset Fig. 1a), which 
is characteristic of the reduced form of graphene oxide 
[14]. UV–Visible spectrum (Fig. 1a) exhibited an absorp-
tion peak at 265  nm, red-shifted when compared with 
graphene oxide, which exhibits a π–π* absorption band 
at 230 nm [15]. The red-shift effect can be explained by 
a partial restoration of the π network among carbons in 
rGO, due to removal of the oxygen-containing bonds 
resulting in electronic conjugation within reduced sheets 
[16].
rGO was stable in sterile distilled water for over a 
month without forming agglomerates or changing its 
physicochemical characteristics. This relatively stable 
aqueous suspension of rGO can be attributed to the 
electrostatic repulsion due to the negatively charged 
sheets (zeta potential of −25 ±  0.18  mV) and the pres-
ence of residual oxygen functional groups at defect sites 
[17]. For the experiments, freshly-suspended rGO was 
characterized with regard to particle size, zeta potential 
and polydispersity index (PDI) by dynamic light scatter-
ing analysis at pH 7.6 and 25  °C; rGO showed an aver-
age diameter of 342 ± 23.5 nm and a PDI of 0.56 ± 0.03. 
These results indicate that although the rGO was nano-
size scale it was polydispersed, as indicated by the PDI 
value.
The surface morphology and structural parameters of 
the samples were determined by high resolution trans-
mission electron microscopy (HRTEM) and Raman spec-
troscopy, respectively. Raman spectroscopy is one of the 
most powerful techniques for characterizing graphene-
based materials [18]. The rGO sheet seen by HRTEM 
(Fig. 1b) had a relatively large surface area and its mor-
phology resembled a thin curtain. The Raman spectrum 
of rGO displayed two main bands, D (1350 cm−1) and G 
(1598 cm−1) (Fig. 1c). These vibrational band signatures 
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are shared by all sp2-bonded carbon atoms and corre-
spond to the defects or edges (D-band) and to the first 
order Raman scattering in the E2 g mode (G-band) [19].
rGO distribution in the brain as determined by MALDI‑MSI
MALDI-MSI has previously been used to locate drugs 
[20, 21] and lipids [22] in rodent brains. In the present 
study, MALDI-MSI was used to demonstrate the pres-
ence, distribution and density of rGO within the brain 
over time. To map rGO by MALDI-MSI, we used a pro-
tocol established for general sample processing that 
included matrix-assisted laser desorption/ionization, 
mass analysis and image registration. A detailed step-by-
step description and discussion of the MALDI-MSI tech-
nique has been published [23, 24]. Although common to 
all MSI platforms, the general procedure described here 
requires optimization of the experimental conditions to 
suit the biological samples in order to obtain the best 
results.
After adjusting our experimental model with regard 
to sample preparation and matrix application, the frag-
mentation pattern of the rGO was confirmed. The laser 
scanning of the tissue sections revealed four dominant 
peaks at mass-to-charge (m/z) ratios of 285, 421, 465 and 
509 (Fig. 2). The fragmentation pattern was the same for 
every rGO administration.
Based on the mass-to-charge ratios of the ions 
detected, composite images were constructed by map-
ping the distribution of rGO throughout the rat brain 
over time (data not shown). The yellow points in Fig.  3 
represent the abundance of ions with the molecular mass 
m/z 465 located in rat coronal brain sections (Fig. 3a–d).
Fig. 1 rGO morphology and physicochemical characterization. a UV–Visible absorbance spectrum of rGO (70 µg/ml, 265 nm). Inset shows the 
corresponding rGO suspension photograph. b HRTEM image showing part of the rGO morphology. c Raman spectrum of rGO with the excitation 
wavelength set to 514.5 nm (Ar ion laser). The C–C sp3 peak of the GO appears at ~1350 cm−1 (D‑band) and the sp2 peak at ~1598 cm−1 (G‑band). 
a.u. arbitrary units
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MALDI-MSI revealed the uptake of rGO and demon-
strated their spatial and temporal distribution. At 15 min 
post-administration, rGO was distributed throughout 
the brain, with the highest concentration being located 
mainly in two brain regions, the thalamus and hip-
pocampus. Quantitative analysis of the mean of pixel 
densities (ion intensity) as a function of the rGO density 
and measured in the two brain regions revealed a sig-
nificant progressive increase in rGO content during the 
first 3  h (Fig.  3f ); this increase indicated a continuous 
movement of rGO from peripheral blood into the brain; 
7  days after rGO administration the nanomaterial con-
tent was still significantly higher than in the control, and 
an increase equal in magnitude to that seen 15 min after 
Fig. 2 Compiled mass spectra of a an aqueous suspension of rGO and b hippocampal tissue 1 h after rGO injection in rats. The data were collected 
in negative ion mode using sinapic acid as the matrix
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administration. This reduction in content at 7 days indi-
cated rGO clearance from the brain.
The large size of rGO (342 ± 23.5 nm) was apparently 
not an obstacle to their entrance into the brain. Very 
few reports have described the presence of large parti-
cles (~200–400  nm) inside the brain [25, 26] and none 
of them provides a clear explanation of the mechanism 
by which nanoparticles reach the brain. An understand-
ing of how larger particles enter the brain is of interest 
because this would allow better efficiency in drug load-
ing, greater dispersion of drugs, and drug release over 
longer periods of time [27, 28].
rGO detection by confocal laser microscopy
The presence of rGO inside the brain as detected by 
MALDI images was corroborated by using confocal laser 
microscopy. After using two-photon excitation with 780-
nm laser pulses, rGO emits fluorescence, mostly in the 
Fig. 3 MALDI‑MSI images of a coronal section of rat brain tissue and the density of rGO in the brain. The rats received a single dose (7 mg/kg) of 
rGO via tail vein and were killed at a 15 min, b 1 h, c 3 h and d 7 days after administration. e Representative distribution of m/z 465 signal in control 
animals; the central black dashed line delineates the hippocampus boundaries. The color scale shows the ion intensity of the rGO (blue color for the 
lowest signal and yellow/red color for highest). The evaluation in arbitrary units (a.u.) of pixels intensity (shown in f) was normalized by discount‑
ing the matrix background. f Quantification of rGO in brain at different times after administration. The columns represent the mean ± SEM (n = 3 
images/interval; one image per animal). *p < 0.05 and ***p < 0.001 compared to the corresponding control. ##p < 0.01 and ###p < 0.001 between 
rGO‑treated time‑points (one‑way ANOVA followed by the Bonferroni post hoc test)
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orange-red region of the visible spectrum. The presence 
of rGO was detected throughout the brain parenchyma, 
but their density was highest in the thalamus and also 
with relevant density in hippocampus, with the intensity 
of fluorescence indicating the spatial abundance. Figure 4 
illustrates the presence of fluorescent rGO in the hip-
pocampus, with predominance of rGO clusters in the 
dentate gyrus.
Evaluation of BBB integrity
We next examined whether the time-related movement 
of rGO into the brain of treated rats, as documented by 
MALDI-MSI and confocal laser microscopy, involved 
breakdown of the BBB. Figures 3 and 4 gave evidences of 
the presence of rGO inside the brain parenchyma but did 
not show the nanoparticles crossing the BBB. As men-
tioned earlier, the mechanism by which nanoparticles 
reach the brain is of medical interest [29]. We hypoth-
esized that for rGO to get access into the brain, the BBB 
had to have been disrupted once the BBB is the fence 
interposed between the peripheral blood stream (through 
which the nanoparticles were administered through the 
tail vein) and the brain. In addition, it would be neces-
sary to determine which transport route was affected. To 
examine such questions, three-resolution level investiga-
tions were implemented.
Gross anatomical evaluation level
BBB integrity was initially assessed based on gross ana-
tomical observation after peripheral i.v. infusion of the 
vital dye Evans blue. Since infused Evans blue dye can-
not permeate an intact BBB [30], any entry of the dye 
into and spread within the brain is indicative of a leaky 
BBB. The systemic infusion of Evans blue in treated con-
trol rats did not alter the typical pink color of fresh brain 
(Fig. 5a). In contrast, in rats administered rGO, the brain 
was stained a bluish gray color, indicating leakage of the 
dye from peripheral bloodstream into the brain paren-
chyma; this staining provided unmistakable evidence 
of BBB opening (Fig.  5b). This disruptive effect on the 
BBB was transient and reversible, since dye leakage was 
observed at 15 min, 1 and 3 h following administration of 
rGO, but was absent at 7 days. Staining with Evans blue 
has long been used in different experimental models as a 
reliable method for assessing BBB integrity and/or leaki-
ness [31, 32].
Subcellular evaluation level of BBB opening based on TEM
TEM was used to assess whether hippocampal capillar-
ies were permeable to the infusion of an electron dense 
extracellular tracer (lanthanum nitrate) after systemic 
administration of rGO. Figure 6 shows capillaries in the 
hippocampal parenchyma of control and rGO-treated 
rats that were systemically perfused with fixative con-
taining the electron opaque extracellular tracer. In con-
trol rats, lanthanum nitrate was confined to the capillary 
lumen and the surrounding neuropile showed mito-
chondria, unmyelinated axons and synaptic contacts 
apparently normal-looking (Fig. 6a). In contrast, in cap-
illaries of treated rats the extracellular tracer infiltrated 
the endothelial cleft, indicating a decrease in the para-
cellular tightness of the barrier after exposure to rGO 
(Fig.  6b; insets show details of the interendothelial cleft 
filled with tracer). This feature was more frequent at 3 h 
and was not observed at 7  days after rGO administra-
tion. The perivascular end-feet processes of astrocytes 
Fig. 4 Visualization of rGO by confocal laser microscopy and light microscopy. Representative confocal micrographs of hippocampus at the 
right cerebral hemisphere from: a vehicle‑injected (control) rats showing none evidence of nanoparticles and b rGO‑treated rats (1 h) showing 
differently‑sized red dots that indicate the differential accumulation of nanoparticles, mainly in the dentate gyrus. Images were obtained at an exci‑
tation wavelength of 365 nm. c Bright field image of paraffin‑embedded hippocampus (captured from the same region as a and b panels) from rats 
administered rGO (1 h): there were no morphologically detectable alterations. Hematoxilyn‑eosin. Scale bars 20 μm (a, b) and 200 μm (c)
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encircling leaked capillaries appeared swollen and were 
suggestive of cytotoxic edema. This was yet another indi-
cation that the BBB permeability was altered by the i.v. 
peripheral injection of rGO [33]. However, despite these 
changes, no extracellular tracer was observed filling the 
basement membrane or spreading through the neuropil 
interstitium. This finding suggested that rGO-induced 
alterations in the BBB did not cause vasogenic edema but 
simply induced abnormal astrocyte osmoregulation [34].
Detailed ultrastructural observations showed that leak-
age of the paracellular barrier was regionally highly het-
erogeneous since in some capillaries of rGO-treated rats 
the lanthanum nitrate was confined to the lumen, as in 
the controls. This finding suggested that the tightness 
of the BBB varied throughout the hippocampal paren-
chyma; regional heterogeneity in the permeability of the 
brain vasculature and tightness of the BBB, even in the 
same vascular segment, is not uncommon and has been 
well-documented [35].
Molecular evaluation level by WB of hippocampal BBB 
paracellular pathway proteins
The western blotting analysis showing that the pro-
teins associated with the impermeability of the BBB 
were down-regulated corroborated the TEM findings 
showing the extravasation of extracellular tracer at 1 h 
and 3  h post-rGO injection (Fig.  7). The expression 
of tight junction protein occludin, adherens junction 
protein β-catenin, and laminin from basal lamina was 
down-regulated at the same periods after rGO injec-
tion as shown by TEM. Occludin was the first protein 
to be affected, with significant downregulation (36 %) 
15  min after rGO administration that reached 66  % 
after 1 h. β-catenin and laminin were decreased by 72 
and 51 % at 1 h and 54 and 84 %, at 3 h, respectively. 
Fig. 5 Gross view of a whole brain after infusion with Evans blue dye. a Note that none of the dye escaped from the vascular bed in control rat 
brain, whereas (b) dye escaped from the vascular bed in the brain after 3 h of rGO administration, indicating blood–brain barrier leakage
Fig. 6 Electron micrographs of rat hippocampal capillaries. a Control 
showing the electron‑opaque extracellular tracer (lanthanum nitrate) 
confined to the capillary lumen. b Capillary 1 h and c 3 h following 
rGO administration. Note that lanthanum nitrate lining the luminal 
inner surface is leaking through the inter‑endothelial contact (black 
boxes). Insets show higher magnification of the contacts. Ax axon, E 
endothelial cell, m mitochondria, P pericyte; asterisk: lumen; double 
asterisk, Dashed line delineates regions of cytotoxic edema in perivas‑
cular astrocytes. Bars 2 μm (a, c), 1 μm (b, inset c), 200 nm (inset b)
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The immediate decrease in the levels of occludin and 
the ensuing decrease of laminin and β-catenin indi-
cated that the systemic administration of rGO was able 
to disturb the paracellular permeability of the BBB. 
By day 7, the expression of all proteins had returned 
to control levels (Fig.  7a–c). These findings agreed 
with the progressive entry of rGO (15 min to 3 h) into 
the brain and their tendency to decrease to baseline 
(7  days) seen with MALDI-MSI. The short-lived dis-
ruption seen here indicated the reversible nature of 
the interference in BBB permeability caused by the 
rGO and confirmed a protective role for the BBB in 
normal brain function. In addition, the persistence 
of rGO within the brain for at least 1 week (as meas-
ured by MALDI-MSI) represents a good prospect for 
therapeutic strategies aimed at the long-term delivery 
of drugs [36] while at the same time reducing possi-
ble side-effects. Based on the findings of this study, we 
suggest that the use of rGO could be advantageous rel-
ative to other non-invasive approaches that disrupt the 
BBB, such as the use of ultrasound [37], hyperosmolar 
osmotic solutions (mannitol) [38] and pharmacologi-
cal agents (histamine and bradykinin) [39] because of 
their ability to simultaneously modulate BBB perme-
ability and act as drug delivery promoters.
Conclusions
We have characterized rGO produced in our labo-
ratory and have described a novel application for 
MALDI-MSI in detecting the possible presence and 
temporal distribution of these particles in the brain 
after intravenous administration in rats. Although 
Fig. 7 Molecular evaluation of hippocampal BBB paracellular pathway proteins as assessed by Western blotting. The panels show the expres‑
sion of a occludin, b β‑catenin and c laminin at different intervals after rGO administration (7 mg/kg, i.v.). Immunoreactive bands were quantified 
densitometrically and normalized to an internal standard (β‑actin). The columns are the mean ± SEM (n = 5 rats/interval). *p < 0.05, **p < 0.01 and 
***p < 0.001 compared to the corresponding control (Student’s t‑test)
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the crossing of rGO at the BBB was not shown, mul-
tiple resolution scale assessment revealed that in 
rGO-treated rats the BBB was time-dependently per-
meabilized through the weakening of the paracellular 
pathway. The transitory BBB breakdown after rGO 
injection was demonstrated by the passage of Evans 
blue dye from peripheral circulation to the brain, by 
lanthanum nitrate infiltration into the inter-endothe-
lial cleft and by down-regulation of tight junction, 
adhesion junction and basement membrane proteins. 
Together, these findings indicate that administration 
of rGO decreases the paracellular tightness of the BBB 
(Fig. 8).
Although we still have to assess the toxicological 
effects of rGO, the results presented here suggest that 
rGO could be useful in providing nanomaterial-based 
therapy. Mainly, this could be potentially useful tool for 
treating a variety of brain disorders that are normally 
unresponsive to conventional treatment because of BBB 
impermeability.
Methods
rGO preparation and characterization
rGO was produced from catalytic conversion using hot-
filament chemical vapor deposition process. Briefly, 
titanium substrate was immersed in 1  ml of polyaniline 
diluted in 2  ml of N-dimethylformamide, after which it 
was allowed drying for 2  h at room temperature. Then, 
0.2 ml of nickel nitrate dissolved in 1 ml of pure acetone 
was added to the preparation. In the chemical vapor 
deposition chamber, tungsten filaments were heated 
(1500  °C) to decompose the reactive gases and heat the 
substrate. The hydrocarbons used as a carbon source 
were acetone, camphor and citric acid (1:1:1), which 
were dragged by hydrogen flow. The catalytic conver-
sion is conducted under 10 Torr pressure and 65 sccm of 
nitrogen and 20 sccm of oxygen. The growth temperature 
(450 °C) was kept for 1 min in only hydrogen atmosphere 
in order to reduce the graphene oxide. After reduction, 
rGO was suspended in sterile distilled water (1  mg/ml) 
and sonicated for 5  min immediately prior to its use in 
experiments.
Morphological analysis of the sample was done with 
HRTEM. A drop of rGO aqueous suspension was depos-
ited on carbon-coated copper grid. The excess water 
was removed by a filter paper; then, the samples were 
left to dry under ambient air and analyzed using a JEOL 
JSM-6330F microscope operated at 300 kV. The molecu-
lar structure was characterized by inVia Raman micro-
scope (Renishaw, Wotton-under-Edge, UK) using the 
514  nm wavelength of an argon-ion laser. All samples 
were deposited onto glass slides in powdered form with-
out using vehicle. Absorption spectrum (800–200  nm) 
of rGO (70  µg/ml) was recorded at room temperature 
using a Varian Cary 5. rGO size distribution was meas-
ured by light scattering using a ZetaPALS Zeta Potential 
Analyzer (Brookhaven Instruments, NY, USA) at stand-
ard settings, typically 10 sub-runs of 30  s. Particle size 
and PDI were estimated using built-in software. The 
zeta potential was subsequently measured in the same 
sample using a conditioned electrode and was typically 
based on 10 runs in which the relative residual from 
model fitting was used. Each sample was measured three 
times consecutively.
Animal care and rGO systemic administration
Male Wistar rats (Rattus norvegicus, 6  week-old, 
180 ± 40 g) obtained from the Multidisciplinary Center 
Fig. 8 Schematic representation of the present experimental design aimed at demonstrating nanomaterial‑based opening of the blood–brain 
barrier
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for Biological Investigation at the State University of 
Campinas were housed 5/cage at 23  °C on a 12 h light/
dark cycle, with lights on at 6 a.m. and access to water and 
food ad libitum. The animal experiments were approved 
by the institutional Committee for Ethics in Animal Use 
(protocol no. 2884-1) and were done in accordance with 
the ethical guidelines of the Brazilian Society of Labora-
tory Animal Science.
For toxicological assessment of nanomaterials involving 
intravenous (i.v.) administration, the stock solution con-
centrations of water-dispersible carbon nanostructures 
are generally ≤10 mg/ml and the maximum permissible 
dose is <10  mg/kg [40, 41]. Based on these guidelines, 
rats were injected via tail vein with a rGO suspension 
(7  mg/kg; 1.0–1.5  ml) or vehicle (sterile distilled water, 
control group) and, after 15 min, 1 and 3 h and 7 days, 
the rats (n = 3 per time interval for MALDI-MSI/confo-
cal laser microscopy; n =  3 per time interval for Evans 
blue; n = 3 per time interval for TEM and n = 5 per time 
interval for WB) were killed with an overdose of a mix-
ture (3:1) of ketamine chloride (Dopalen®, 100  mg/kg 
body weight) and xylazine chloride (Anasedan®, 10 mg/
kg body weight) (Vetbrands, Jacarei, SP, Brazil) or CO2. 
A single control group killed 1  h after vehicle injection 
was used for comparison (n  =  14) since preliminary 
experiments showed no time-related differences in the 
responses of control rats.
Detection of rGO in the brain
MALDI‑MSI analysis
At the time intervals indicated above, rats were anesthe-
tized with an intraperitoneal injection of a mixture of 
ketamine chloride and xylazine chloride and perfused 
via the left ventricle with physiological saline followed by 
4 % paraformaldehyde (PFA) in 0.1 M phosphate buffered 
saline (PBS), pH 7.4. The brains were quickly removed, 
post-fixed for 2 h in the same fixative and afterward suc-
cessively cryo-protected in 15 and 30 % sucrose solutions 
(24 h each) at 4 °C. Since brain tissue is very friable, the 
samples were embedded in OCT-Tissue Tek (Sakura 
Finetek, Torrance, CA, USA) and frozen in n-hexane 
(Dinâmica, São Paulo, SP, Brazil), cooled with liquid 
nitrogen and stored at −80  °C until cryo-sectioning 
(Leica CM 1850 Cryostat; Milton Keynes, UK). Cryo-
sections 10 μm thick were collected on glass microscope 
slides that were then covered with a matrix solution 
(synapic acid, 10 mg/ml in 60:40 acetonitrile:H2O) using 
a commercial airbrush. Images and mass spectra were 
acquired in a MALDI-LTQ-XL MSI instrument (Thermo 
Scientific, Carlsbad, CA, USA) equipped with a laser 
(Nd:YAG, 355  nm) at minimum focus setting and a 
quadrupole-ion-trap analyzing system in negative ion 
mode. For image acquisition, a 100 µm raster width was 
selected. The data were standardized using collision-
induced energy to 35 eV. Helium was used as the collision 
gas. All imaging data were processed using ImageQuest 
software v.1.0.1 (Thermo Scientific).
Mass and intensity values for each spectrum were 
included in the Principal Component Analysis (PCA), 
which was performed using Unscrambler v.9.7 (CAMO 
Software, Trondheim, Norway). After discrimination by 
PCA, MS/MS reactions were performed to generate their 
fragmentation pattern.
The quantification and distribution of rGO in the brain 
were assessed using GNU Image Manipulation Program 
(GIMP) 2.8 software that converted the digitized MALDI 
images to grayscale images (n = 3 images/time, i.e., one 
image per rat; n = 3 rats/time) after yellow color-based 
selection [42]; in each image, the range of yellows shad-
ing the dots, and representing the rGO depth into tissue, 
were selected dynamically by the program which thus 
converted them to digitized grayscale dots and further to 
pixels’ intensity. The mean of the sum of pixels in each 
time point was plotted as histogram. The red dots were 
not computed in terms of pixels given its paucity and 
minimal distribution. Figure 9 illustrates the appearance 
of spatial distribution of yellow dots representing rGO 
nanoparticles following computer-based image conver-
sion to digitized grayscale.
Confocal laser microscopy analysis
The same samples prepared for MALDI-MSI analysis 
were examined using a Zeiss LSM 780-NLO confocal 
imager fitted on an Axio Observer Z.1 microscope (Carl 
Zeiss AG, Germany) equipped with a 60× oil immersion 
lens. The images were acquired using the pinholes set to 
1 airy unit for each channel in a sequential manner and 
analyzed using ImageJ 1.45  s software (NIH, Bethesda, 
USA). The images of rGO were obtained using two-pho-
ton  excitation  with 780-nm laser pulses and emission 
spectra were recorded between 611 and 735 nm [43, 44].
Evaluation of BBB integrity
Gross analysis by Evans blue peripheral infusion
BBB integrity was first examined by assessing Evans blue 
dye extravasation [45] Briefly, 10  min prior the end of 
each time course, Evans blue dye solution was injected 
(10  mg/kg of 2  % dye in 0.9  % NaCl) intravenously 
through the tail vein. Animals were killed with an over-
dose of anesthetic and the brains were rapidly removed 
and photographed.
Ultrastructural analysis of extracellular tracer leakage
One hour after vehicle administration and at various 
intervals after rGO injection, rats were anesthetized with 
ketamine/xylazine and  killed by transcardial perfusion 
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with 80 ml of 0.9 % NaCl followed by 250 ml of fixative 
solution (2.5 % PFA, 2.5 % glutaraldehyde plus 2 % lan-
thanum nitrate in 0.1  M sodium cacodylate, pH 7.2) 
as described in previous study [46, 47]. The rats were 
maintained at 4  °C for 12–18  h to allow adequate fixa-
tion before brain dissection and processing in order to 
minimize tissue artifacts. The brain was then excised 
and the hippocampi were dissected. Hippocampi were 
selected for analysis because this was a brain region in 
which an appreciable concentration of rGO was found 
by MALDI-MSI. Tissue samples 0.5–1  mm thick were 
immersed in the same fixative (lanthanum nitrate-free) 
for 2 h. After rinsing, the samples were post-fixed in 1 % 
osmium tetroxide plus 1 % potassium ferricyanide in glu-
cose solution (0.2  M sucrose plus 0.1  M NaCl) for 1  h, 
washed three times and dehydrated in a graded ethanol 
series (50–100  %), ethanol:acetone (1:1) and 100  % ace-
tone, followed by infiltration with acetone:Epon (1:1) and 
embedding in Epon 812 (Sigma Aldrich, St. Louis, MO, 
USA) resin for 24  h at room temperature. The samples 
were subsequently transferred to fresh resin for polym-
erization (72 h at 60 °C). The areas of interest were cho-
sen by histological analysis of semi-thin sections (0.5 μm 
thick) stained with 0.5 % toluidine blue. Ultrathin (70 nm 
thick) sections from selected areas were placed on 200-
mesh copper grids, double contrasted with 2  %  uranyl 
acetate (in 70 % methanol) followed by 0.5 % lead citrate 
aqueous solution before examination in a Zeiss LEO 906 
transmission electron microscope (Carl Zeiss MicroIm-
aging GmbH, Göttingen, Germany) operated at 60 kV.
Western blotting of proteins associated with the BBB 
in hippocampal homogenates
At 15 min, 1 h, 3 h and 7 days after rGO i.v. injection or 
1 h after vehicle injection, the rats were anesthetized by 
CO2 inhalation and killed by decapitation. Protein was 
extracted from hippocampus as previously described 
[48]. After electrotransfer, the membranes were incu-
bated with 5 % skimmed milk to block non-specific sites 
prior followed by washing with TBS-T (0.1 % Tris-buff-
ered saline with 0.05 % Tween 20, pH 7.4). Subsequently, 
the membranes were incubated with primary antibodies 
against β-catenin (1:500; sc-7963, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), occludin (1:500; sc-5562, 
Santa Cruz) and laminin (1:500; L9393, Sigma Aldrich) 
followed by washing with TBS-T and incubation with 
HRP-labeled anti-mouse (for anti-β-catenin and anti-
β-actin) or anti-rabbit (anti-occludin and anti-laminin) 
secondary antibody (1:1000, Sigma Aldrich). Immunore-
active bands were visualized using a chemiluminescence 
kit (Super Signal West Pico Chemiluminescent Substrate; 
Pierce Biotechnology, Rockford, IL, USA). The blots 
were subsequently stripped and probed with anti-β-actin 
(1:1000; A2228, Sigma Aldrich); β-actin was used as an 
internal control to monitor protein loading, the efficiency 
of blot transfer, and nonspecific changes in protein levels. 
The luminescent signal of each band was captured with 
a G:BoxiChemi camera (Syngene, Cambridge, UK) and 
band intensity was quantified using ImageJ 1.45  s soft-
ware (NIH, Bethesda, MD, USA).
Statistical analysis
Quantitative data were expressed as the mean ±  stand-
ard error of the mean (SEM). Statistical significance was 
determined by one-way ANOVA followed by the Bon-
ferroni post hoc test for multiple variant analysis and 
Student’s t test for pairwise analyses. A value of p < 0.05 
indicated significance. All analyses were done using 
Prism software, version 5 (GraphPad Inc., La Jolla, CA, 
USA).
Fig. 9 Methodology used for quantitative analysis of rGO. a Representative MALDI‑mass spectrometry imaging of rGO‑treated brain section 
(Fig. 3c). b The same section after color segmentation using GIMP 2.8 software
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